Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma

Roy E. Strowd, Inas A. Abuali, Stuart A. Grossman

Research output: Contribution to journalArticlepeer-review

Abstract

Indolent CNS lymphomas (CNSLs) are rare and no guidelines exist for management. Recent literature highlights the potential for safe and tolerable intrathecal (IT) delivery of rituximab, a large anti-CD20 monoclonal antibody, for aggressive CNSL. We report a patient with relapsed indolent CNSL who failed systemic rituximab and could not tolerate IT chemotherapies, but had an objective response of 6 months duration to IT rituximab.

Original languageEnglish (US)
Pages (from-to)131-135
Number of pages5
JournalCNS oncology
Volume4
Issue number3
DOIs
StatePublished - 2015

Keywords

  • CNS lymphoma
  • indolent lymphoma
  • intrathecal rituximab
  • low-grade lymphoma

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma'. Together they form a unique fingerprint.

Cite this